Eptinezumab
Eptinezumab is a monoclonal antibody medication used for the preventive treatment of migraine in adults. It works by binding to and blocking calcitonin gene-related peptide (CGRP), a protein that plays a key role in triggering migraine attacks. This medication is administered via intravenous infusion and is designed to reduce the frequency and severity of migraine episodes.
Eptinezumab is an IV-administered monoclonal antibody that prevents migraines by blocking CGRP, a key migraine-triggering protein.
Key facts at a glance
- ATC
- N02CD05
- RxNorm
- 2282660
- Generic
- Eptinezumab
- Class
- atc-n02
- Brands
- Vyepti
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 100mg every 12 weeks
- Maximum
- consult physician
- Frequency
- every 12 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 300mg every 12 weeks
- Maximum
- consult physician
- Frequency
- every 12 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 100mg every 12 weeks
- Maximum
- consult physician
- Frequency
- every 12 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteruse with caution
use only if benefits outweigh potential risks to fetus
regular fetal monitoring and ultrasound assessments
Use with caution and monitor for adverse effects.
pregnancy
third trimesteruse with caution
use only if benefits outweigh potential risks, consider timing near delivery
fetal monitoring and assessment of neonatal outcomes
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
use with caution, monitor infant for potential effects
observe infant for unusual symptoms
pediatric_age
under 18 yearsnot indicated
not recommended for patients under 18 years of age
not established
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
65 years and olderno adjustment needed
can be used at standard dosing in otherwise healthy elderly
standard monitoring as per prescribing guidelines
renal_impairment
mild moderateno adjustment needed
can be used at standard dosing
routine renal function monitoring
renal_impairment
severeuse with caution
use with caution, limited clinical data available
close monitoring of renal function
Use with caution and monitor for adverse effects.
hepatic_impairment
mild moderateno adjustment needed
can be used at standard dosing
routine hepatic function monitoring
Statistics and clinical data
Drug class
Biological product classification for migraine prevention
FDA approval year
Initial FDA approval date for Eptinezumab
Common uses
Therapeutic indication for Eptinezumab
Route of administration
Method of drug delivery
Preventive treatment of episodic and chronic migraine in adults, helping to reduce migraine frequency and severity.
Eptinezumab is a humanized monoclonal antibody that binds specifically to calcitonin gene-related peptide (CGRP) ligand, blocking it from binding to its receptor and preventing the biological processes that initiate migraine attacks.
Administered as an intravenous infusion, typically every 12 weeks. Common side effects may include nasopharyngitis and hypersensitivity reactions. Should be used under healthcare provider supervision. Not indicated for acute migraine treatment.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy